Altered fractionation in the treatment of head and neck cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Several altered fractionation schemes have evolved to exploit different aspects of head and neck cancer growth kinetics and normal tissue repair. Hyperfractionation schedules exploit the differential repair abilities of tumor and normal tissue, whereas accelerated fractionation regimens minimize the time of tumor repopulation. Significant clinical data have accumulated that indicate an improvement between 15% and 20% in locoregional control from altered fractionation. Preliminary analysis of a randomized Radiation Therapy Oncology Group trial testing four fractionation schemes confirms the benefit of one altered fractionation approach. Several promising concurrent chemoradiation treatments involving altered fractionation have been reported. Future trials will determine whether the addition of chemotherapy to altered fractionation schemes is warranted in light of the factor of added toxicity.
- Million RR, Cassisi NJ: Management of head and neck cancer, a multidisciplinary approach, In edn 2. Philadelphia: JB Lippincott; 1994.
- Harrison LB, Sessions RB, Hong WK: Head and neck cancer, a multidisciplinary approach. In Philadelphia: Lippincott-Raven; 1999.
- Withers HR: Biologic basis for altered fractionation schemes. Cancer 1985, 55(9 suppl):2086–2095. CrossRef
- Withers HR, Taylor JM, Maciejewski B: The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131–146. This paper summarizes the clinical data that supports the hypothesis of “accelerated repopulation” of tumor clonogens of head and neck cancer after 4 weeks of treatment. The concept underlies the current understanding of head and neck cancer growth kinetics.
- Hansen O, Ovargaard J, Hansen HS, et al.: Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol 1997. 43:47–51. CrossRef
- Cox JD, Pajak TF, Marcial VA, et al.: Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts: new evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer 1992, 69:2744–2748. CrossRef
- Wang CC, Efird J, Hakfor B, Martins P, et al.: Local control of T3 carcinomas after accelerated fractionation: a look at the “gap.” Int J Radiat Oncol Biol Phys 1996, 35:439–441. CrossRef
- Overgaard J, Hjelm-Hansen M, Johansen LV, Andersen AP, et al.: Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 1988, 27:147–145.
- Ang, KK: Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 1998, 8:230–236. CrossRef
- Jackson SM, Weir LM, Hay JH, et al.: A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 43:39–46. CrossRef
- Overgaard J, Hansen HS, Sapru W: Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck: a randomized multicenter study of 5 versus 6 fractions per week preliminary from DAHANCA 6 and 7 trial. Radiother Oncol 1996, 40(suppl):S31. CrossRef
- Wang CC, Blitzer PH, Suit HD: Twice-a-day radiation therapy for cancer of the head and neck. Cancer 1985, 55(suppl):2100–2104. CrossRef
- Wang CC: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 1988, 14:1143–1146.
- Wang CC: Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx: techniques and results. Cancer 1989, 63:2461–2467. CrossRef
- Horiot JC, Bontemps P, Van den Bogaert W, et al.: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997, 44:111–121. CrossRef
- Van den Bogaert W, Van der Schueren E, Horiot JC, et al.: The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol 1995, 35:91–99. CrossRef
- Cox JD, Pajak TF, Marcial VA, et al.: Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. Int J Radiat Oncol Biol Phys 1990, 18:515–521.
- Mendenhall WM, Parsons JT: Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. Cancer Invest 1998. 16:594–603.
- Million RR, Parsons JT, Cassisi NJ: Twice-a-day irradiation technique for squamous cell carcinomas of the head and neck. Cancer 1985, 55(suppl):2096–2099. CrossRef
- Cummings BJ: Benefits of accelerated hyperfractionation for head and neck cancer. Acta Oncol 1999, 38:131–136. CrossRef
- Datta NR, Choudhry AD, Gupta S: Twice a day versus once a day radiation therapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1996, 36:235.
- Horiot JC, Le Fur R, N’Guyen T, et al.: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25:231–241. Of the five major randomized trials testing the efficacy of hyperfractionation, the trial reported here represents the clearest randomized evidence of locoregional control benefit. CrossRef
- Pinto LH, Canary PC, Araujo CM, et al.: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1991, 21:557–562.
- Sanchiz F, Milla A, Torner J, et al.: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck. Int J Radiat Oncol Biol Phys 1990, 19:1347–1350.
- Dische S, Saunders M, Barrett A, et al.: a randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44:123–136. CrossRef
- Peters LJ, Ang KK, Thames HD Jr.: Accelerated fractionation in the radiation treatment of head and neck cancer. a critical comparison of different strategies. Acta Oncol 1988, 27:185–194.
- Ang KK, Peters LJ, Weber RS, et al.: Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990, 19:1339–1345.
- Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991, 324:1685–1690. CrossRef
- Lefebvre JL, Chevalier D, Luboinski B, et al.: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996, 88:890–899. CrossRef
- Forastiere AA: Larynx preservation trials: a critical appraisal. Semin Radiat Oncol 1998, 8:254–261. CrossRef
- Fu KK: Combined-modality therapy for head and neck cancer. Oncology 1997, 11:1781–1800.
- Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310–1317. An important trial confirming the benefit of concurrent chemotherapy with conventional fractionation compared to radiation alone for treatment of advanced nasopharyngeal cancers. This trial redefines the standard of care for treatment of this disease.
- Laramore GE, Scott CB, Al-Sarraf M, et al.: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992, 23:705–713.
- Brizel DM, Albers ME, Fisher SR, et al.: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798–1804. One of the first published randomized trials testing whether concurrent chemotherapy enhances the efficacy of hyperfractionation. Patients developed significant added toxicity but appeared to have a locoregional benefit from combined treatment. The two arms of the trial were not balanced with respect to patients with advanced nodal disease. CrossRef
- de Serdio JL, Villar A, Martinez JC, et al.: Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced head and neck cancer. Head Neck 1998, 20:489–496. A phase II trial that showed excellent tolerance of a novel approach to chemotherapy delivery concurrent with radiation. Preliminary results are encouraging. CrossRef
- Harrison LB, Lee HJ, Pfister DG, et al.: a prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck 1998, 20:497–503. A phase II trial reporting the use of concurrent chemotherapy with delayed concomitant boost radiation. The results of treatment in a challenging group of patients were promising. The importance of this approach is highlighted by preliminary results from RTOG 90-03 showing that delayed concomitant boost yielded the best results of four fractionation schemes. CrossRef
- Looney WB, Goldie JH, Little JB, et al.: Alternation of chemotherapy and radiotherapy in cancer management. I. Summary of the division of cancer treatment workshop. Cancer Treat Report 1985, 69:769–775.
- Merlano M, Benasso M, Corvo R, et al.: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992, 327:1115–1121. A landmark trial that demonstrated improved locoregional and survival benefit from concurrent chemoradiation compared with conventional radiation alone without significant radiation-related toxicity. This novel approach challenges the basic tenet of radiation oncologists to avoid split-course irradiation. CrossRef
- Merlano M, Benasso M, Corvo R, et al.: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996, 88:583–589. CrossRef
- Merlano M, Rosso R, Sertoli MR, et al.: Randomized comparison of two chemotherapy, radiotherapy schemes for stage III and IV unresectable squamous cell carcinoma of the head and neck. Laryngoscope 1990, 100:531–535. CrossRef
- Merlano M, Corvo R, Margariano G, et al.: Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck: the final report of a randomized trial. Cancer 1991, 67:915–921. CrossRef
- Taylor SGT IV, Murthy AK, Griem KL, et al.: Concomitant cisplatin/ 5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck 1997, 19:684–691. CrossRef
- Taylor SGT IV, Murthy AE, Vannetzel JM, et al.: Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994, 12:385–395.
- Altered fractionation in the treatment of head and neck cancer
Current Oncology Reports
Volume 1, Issue 2 , pp 110-123
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. The Charles and Bernice Blitman Department of Radiation Oncology, Beth Israel Medical Center, 10 Union Square East, 10003, New York, NY, USA
- 2. Beth Israel Medical Center and St. Luke’s-Roosevelt Hospital Center, New York, NY